Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine/Islatravir rollover study in HIV-1
NCT04776252Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of doravirine + islatravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Sep 2021; status: active, not recruiting.
02
Drugs
doravirine + islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04776252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776252.